LON:FAB

Fusion Antibodies (FAB) Share Forecast, Price & News

GBX 55.50

0.00 (0.00%)

(As of 05/27/2022 12:00 AM ET)

Add

Compare

Today's Range: 53
▼
55.50
50-Day Range: 53
▼
69.50
52-Week Range: 53
▼
149.25

Volume: 7,461 shs
Average Volume: 24,281 shs
Market Capitalization: £14.44 million

P/E Ratio: N/A
Dividend Yield: N/A
Beta: N/A

30 days | 90 days | 365 days | Advanced Chart

Receive FAB News and Ratings via Email

Sign-up to receive the latest news and ratings for Fusion Antibodies and its competitors with MarketBeat's FREE daily newsletter.

About Fusion Antibodies

Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. It offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services. The company serves pharmaceutical, biotech, and diagnostic companies. It has a collaboration partnership with Celonic AG. Fusion Antibodies plc was incorporated in 2000 and is headquartered in Belfast, the United Kingdom.

May 6, 2022 | lse.co.uk

Fusion Antibodies annual revenue grows despite challenges

May 6, 2022 | marketwatch.com

Fusion Antibodies FY 2022 Revenue Rose 14%

April 11, 2022 | forbes.com

Two Emerging Viral Adversaries—Nipah And Hendra Virus—May Soon Meet Their Match

March 29, 2022 | tmcnet.com

Dyadic Reports 2021 Year End Results and Recent Company Progress

March 29, 2022 | forbes.com

New And Effective Monoclonal Antibody Treatment For Ebola On The Horizon

February 22, 2022 | marketwatch.com

Fusion Antibodies CEO Richard Jones Resigns

February 8, 2022 | tmcnet.com

Dyadic International's CEO Mark Emalfarb to Present at BIO CEO & Investor Conference

December 16, 2021 | markets.businessinsider.com

Fusion Antibodies : Exercise of share options and total voting rights

December 12, 2021 | finanznachrichten.de

F. Hoffmann-La Roche Ltd: Roche presents pivotal data at ASH 2021 for novel cancer immunotherapy mosunetuzumab

October 24, 2021 | markets.businessinsider.com

Fusion Antibodies : Grant of options

October 7, 2021 | marketwatch.com

Fusion Antibodies Shares Rise on $1.8 Mln Contract News

September 24, 2021 | marketwatch.com

Fusion Antibodies Says Revenue Growth Is Consistent With Previous Financial Period

September 14, 2021 | finance.yahoo.com

Auburn engineers create device that instantly reveals COVID test results

See More Headlines

Industry, Sector and Symbol

Stock Exchange: LON
Industry: Biotechnology
Sub-Industry: N/A
Sector: Medical
Current Symbol: LON:FAB
Previous Symbol
CUSIP: N/A
CIK: N/A
Web: fusionantibodies.com
Phone: +44-28-90432800
Fax: N/A
Employees: 55
Year Founded: N/A

Sales & Book Value

Annual Sales: £4.70 million
Price / Sales: 3.07
Cash Flow: GBX 7.12 per share
Price / Cash Flow: 7.79
Book Value: GBX 16.40 per share
Price / Book: 3.38

Profitability

EPS (Most Recent Fiscal Year): N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: 3.58
Current Ratio: 4.09
Quick Ratio: 3.58

Price-To-Earnings

Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A

Miscellaneous

Outstanding Shares: 26,015,000
Free Float: N/A
Market Cap: £14.44 million
Optionable: Not Optionable

Company Calendar

Today: 5/27/2022
Next Earnings (Estimated): 8/08/2022

MarketRank^™

Overall MarketRank^™

0.91 out of 5 stars

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Fusion Antibodies.

4.5 Community Rank

Outperform Votes
Fusion Antibodies has received 54 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Fusion Antibodies has received 25 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Fusion Antibodies has received 68.35% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Fusion Antibodies and other stocks. Vote “Outperform” if you believe FAB will outperform the S&P 500 over the long term. Vote “Underperform” if you believe FAB will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Fusion Antibodies does not currently pay a dividend.
Dividend Growth
Fusion Antibodies does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Fusion Antibodies insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Fusion Antibodies is -4.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Fusion Antibodies is -4.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Fusion Antibodies has a P/B Ratio of 3.38. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Fusion Antibodies (LON:FAB) Frequently Asked Questions

When is Fusion Antibodies' next earnings date?: Fusion Antibodies is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Fusion Antibodies.
Who are Fusion Antibodies' key executives?: Fusion Antibodies' management team includes the following people:
Mr. James Fair, CFO, Company Sec. & Director (Age 56, Pay $125k)
Dr. Richard John Buick Ph.D., Chief Scientific Officer & Director (Age 46, Pay $131k)
Dr. Paul Gerard Kerr, Consultant (Age 49, Pay $180.38k)
Prof. Jim Johnston, Founder
Mr. Hugh Morgan Ph.D., Director of Operations
Who are some of Fusion Antibodies' key competitors?: Some companies that are related to Fusion Antibodies include C4X Discovery (C4XD), Unity Biotechnology (UBX), 4basebio (4BB), Covalon Technologies (COV), Acasti Pharma (ACST), Asterias Biotherapeutics (AST), Emerald Health Therapeutics (EMH), Synairgen (SNG), Ceapro (CZO), ProMIS Neurosciences (PMN), Small Pharma (DMT), Sirona Biochem (SBM), SkinBioTherapeutics (SBTX), Brooklyn ImmunoTherapeutics (BTX) and Brooklyn ImmunoTherapeutics (BTX).
View all of FAB's competitors.
What other stocks do shareholders of Fusion Antibodies own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Fusion Antibodies investors own include D4t4 Solutions (D4T4), Aminex (AEX), Eurasia Mining (EUA), Dril-Quip (DRQ), 4D pharma (DDDD), ABM Industries (ABM), Card Factory (CARD), Blockchain Worldwide (BLOC), ATTRAQT Group (ATQT) and (APHA).
What is Fusion Antibodies' stock symbol?: Fusion Antibodies trades on the London Stock Exchange (LON) under the ticker symbol "FAB."
How do I buy shares of Fusion Antibodies?: Shares of FAB and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.
What is Fusion Antibodies' stock price today?: One share of FAB stock can currently be purchased for approximately GBX 55.50.
How much money does Fusion Antibodies make?: Fusion Antibodies has a market capitalization of £14.44 million and generates £4.70 million in revenue each year.
How many employees does Fusion Antibodies have?: Fusion Antibodies employs 55 workers across the globe.
What is Fusion Antibodies' official website?: The official website for Fusion Antibodies is fusionantibodies.com.
How can I contact Fusion Antibodies?: Fusion Antibodies' mailing address is Springbank Industrial Estate 1 Springbank Road, BELFAST, NIR BT17 0QL, United Kingdom. The company can be reached via phone at +44-28-90432800.

This page was last updated on 5/27/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms

Your Ultimate Investing Toolkit

Just $1.00 for your first month.